Pathology: Extensive stage SCLC (Es-SCLC) - maintenance (M); Extensive stage SCLC (Es-SCLC) - 1st Line (L1);
Extensive stage SCLC (Es-SCLC) - maintenance (M) | Extensive stage SCLC (Es-SCLC) - 1st Line (L1) | ||||
CheckMate 451 (N ; all population), 2019 | IMpower-133, 2018 | CASPIAN (D ; all population), 2019 | KEYNOTE-604, 2020 | ||
pembrolizumab plus SoC | 1 | T1 | |||
nivolumab alone | 1 | T1 | |||
durvalumab plus etoposide and platin | 1 | T1 | |||
atezolizumab plus SoC | 1 | T1 | |||
placebo | 0 | T0 | |||
placebo plus SoC | 0 | T0 | T0 | ||
etoposide plus platin | 0 | T0 |